TY  - JOUR
AU  - Pivot, X
AU  - Verma, S
AU  - Fallowfield, L
AU  - Muller, V
AU  - Lichinitser, M
AU  - Jenkins, V
AU  - Sanchez-Muñoz, A
AU  - Machackova, Z
AU  - Osborne, S
AU  - Gligorov, J
PY  - 2017
DO  - 10.1016/j.ejca.2017.08.019
UR  - http://hdl.handle.net/10668/11633
T2  - European journal of cancer (Oxford, England : 1990)
AB  - To assess efficacy (event-free survival, EFS) and safety in patients followed up for 3 years in the PrefHer study (NCT01401166). Post surgery and post chemotherapy in the (neo)adjuvant setting, patients with human epidermal growth factor receptor 2...
LA  - en
PB  - Elsevier
KW  - Breast cancer
KW  - HER2/neu
KW  - Herceptin
KW  - Patient preference
KW  - Subcutaneous
KW  - Trastuzumab
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents, Immunological
KW  - Breast Neoplasms
KW  - Chemotherapy, Adjuvant
KW  - Disease-Free Survival
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Injections, Intravenous
KW  - Injections, Subcutaneous
KW  - Kaplan-Meier Estimate
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Protein Kinase Inhibitors
KW  - Receptor, ErbB-2
KW  - Time Factors
KW  - Trastuzumab
KW  - Treatment Outcome
TI  - Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
TY  - research article
VL  - 86
ER  -